Key Drivers
- High gross margin
- Large opex burden
- Elevated leverage/intangibles
AIAI Summary
GoodRx is now a margin‑rich, deal‑driven B2B distributor—cheap on EV/EBITDA—but investors should only get constructive if management proves repeatable Manufacturer Solutions contract cadence and stabilizes consumer engagement or meaningfully reduces leverage, because revenue will remain lumpy and concentrated until then.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Large opex burden
- •Elevated leverage/intangibles
GDRX combines strong liquidity and cash generation with very high gross margins but is constrained by large operating expenses, significant long‑term leverage and heavy intangibles that suppress net returns.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Held $1.87
- •Resistance cluster
Over the last month GDRX is trending lower—March 20 close $2.03 is below the last-month SMA (~$2.22) with neutral RSI (~47), support held near $1.87 but overhead resistance around $2.22–$2.47 keeps sellers in control until a decisive reclaim.
Recent acceleration to the downside into 2026-03-20
Sentiment & News
Key News Insights:
- •Employer push
- •Manufacturer deals
- •Consumer decline
GoodRx posted modest GAAP profit and solid adjusted EBITDA while pivoting into employer sales and manufacturer partnerships to counter a 14% drop in active consumers and accelerate subscription growth.
The strategic shift toward employer channels and partner-backed savings should stabilize distribution and monetization but requires improved consumer engagement to sustain growth
Similar Companies in Healthcare
Other companies in the same sector with AI ratings